SK bioscience applies for emergency Covid-19 vaccine approval
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
![A bird's-eye view of SK bioscience's vaccine facility in Songdo, Incheon [SK BIOSCIENCE]](https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202310/20/koreajoongangdaily/20231020181618546ribv.jpg)
SK bioscience has applied for emergency use approval for Novavax’s updated Covid-19 vaccine.
SK bioscience is the local distributor of the NVX-CoV2601 vaccine developed by Novavax, exclusively in Korea and non-exclusively in Thailand and Vietnam.
The Seongnam, Gyeonggi-based company said Friday that it submitted an application for emergency use of the updated vaccine to the Korean Ministry of Food and Drug Safety. Upon authorization, SK bioscience will supply the updated Novavax Covid-19 vaccine in Korea during the 2023-2024 winter season.
The protein-based non-mRNA vaccine is the third updated Covid vaccine to be authorized in the United States against the Omicron variant.
SK bioscience made an equity investment in Novavax to become the third-biggest shareholder of the U.S. company in August.
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- Halloween prep turns eerily quiet as Seoul remembers Itaewon crowd crush
- We must ask tough questions in era of misinformation, says New York Times chairman
- Seoul's Zest enters World's 50 Best Bars list
- Actor Ha Seok-jin wins Netflix reality show 'The Devil's Plan'
- Much-maligned map of Seoul's subway to get first revamp in four decades
- Prosecution indicts Yoo Ah-in without detention on drug use charges
- Northeast Asia opportunity in plain sight for Airbus, Boeing
- Seoul criticizes Japanese parliamentarians' visiting Yasukuni Shrine
- Yoon to visit Saudi Arabia, Qatar amid regional turmoil
- AI yearbook picture craze makes it rain for Snow